Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women

Circulation: Cardiovascular Genetics

Volumn 2, Issue 4, 2009, Pages 389-395

  Reuwer, Anne Q ^a   Twickler, Marcel Th B ^a   Hutten, Barbara A ^a   Molema, Frederique W ^b   Wareham, Nicholas J ^c   Dallinga Thie, Geesje M ^a   Bogorad, Roman L ^d   Goffin, Vincent ^d   Smink Bol, Mijke ^b   Kastelein, John J P ^a   Boekholdt, S Matthijs ^a   Khaw, Kay Tee ^e  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b RUN   (Netherlands)

^c MRC EPIDEMIOLOGY UNIT   (United Kingdom)

^d INSERM   (France)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Atherogenesis; Atherosclerosis; Coronary artery disease; Hormones; Inflammation; Prolactin

Indexed keywords

PROLACTIN; PROLACTIN RECEPTOR;

ADULT; AGED; ARTICLE; ATHEROGENESIS; ATHEROSCLEROTIC PLAQUE; CASE CONTROL STUDY; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; ATHEROSCLEROSIS; BLOOD; CORONARY BLOOD VESSEL; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK; RISK FACTOR;

AGED; ATHEROSCLEROSIS; CASE-CONTROL STUDIES; COHORT STUDIES; CORONARY ARTERY DISEASE; CORONARY VESSELS; FEMALE; HUMANS; MALE; MIDDLE AGED; ODDS RATIO; PROLACTIN; RECEPTORS, PROLACTIN; RISK FACTORS;

EID: 77449159580     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.109.853572     Document Type: Article

References (29)

1. Horseman ND. Prolactin and mammary gland Development. J Mammary Gland Biol Neoplasia. 1999;4:79-88.
2. Ben-Jonathan N, LaPensee CR, LaPensee EW. What can we learn from roDents about prolactin in humans? Endocr Rev. 2008;29:1-41.
3. Goffin V, Bernichtein S, Touraine P, Kelly PA. Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev. 2005;26:400-422.
4. Grattan DR, Steyn FJ, Kokay IC, AnDerson GM, Bunn SJ. Pregnancyinduced aDaptation in the neuroendocrine control of prolactin secretion. J Neuroendocrinol. 2008;20:497-507.
5. Raaz D, Wallaschofski H, Stumpf C, Yilmaz A, Cicha I, Klinghammer L, Daniel WG, Lohmann T, Garlichs CD. Increased prolactin in acute coronary syndromes as putative Co-activator of ADP-stimulated P-selectin expression. Horm Metab Res. 2006;38:767-772.
6. Wallaschofski H, Lohmann T, Hild E, Kobsar A, Siegemund A, Spilcke-Liss E, Hentschel B, Stumpf C, Daniel WG, Garlichs CD, Eigenthaler M. Enhanced platelet activation by prolactin in patients with ischemic stroke. Thromb Haemost. 2006;96:38-44.
7. Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G. The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf). 2006;64: 366-370.
8. Yavuz D, Deyneli O, Akpinar I, Yildiz E, Gozu H, Sezgin O, Haklar G, Akalin S. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur J Endocrinol. 2003;149:187-193.
9. Georgiopoulos GA, Stamatelopoulos KS, LambrinouDaki I, Lykka M, Kyrkou K, Rizos D, Creatsa M, Christodoulakos G, Alevizaki M, Sfikakis PP, Papamichael C. Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension. 2009;54: 98-105.
10. Montes De Oca P, Macotela Y, Nava G, Lopez-Barrera F, De la Escalera GM, Clapp C. Prolactin stimulates integrin-mediated adhesion of circulating mononuclear cells to endothelial cells. Lab Invest. 2005;85: 633-642.
11. Sauro MD, Buckley AR, Russell DH, Fitzpatrick DF. Prolactin stimulation of protein kinase C activity in rat aortic smooth muscle. Life Sci. 1989;44:1787-1792.
12. Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation. 2007;116:2694-2701.
13. Razvi S, Shakoor A, VanDerpump M, Weaver JU, Pearce SH. The influence of age on the relationship between subclinical hypothyroidism and ischemic heart disease: a metaanalysis. J Clin Endocrinol Metab. 2008;93:2998-3007.
14. Tauchmanova L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Palmieri EA, Fazio S, Lombardi G. Patients with subclinical Cushing's syndrome due to adrenal aDenoma have increased cardiovascular risk. J Clin Endocrinol Metab. 2002;87:4872-4878.
15. Juul A, Scheike T, Davidsen M, Gyllenborg J, Jorgensen T. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002; 106:939-944.
16. Day N, Oakes S, Luben R, Khaw KT, Bingham S, Welch A, Wareham N. EPIC-Norfolk: study Design and characteristics of the cohort. European Prospective Investigation of Cancer. Br J Cancer. 1999;80(Suppl 1):95-103.
17. Schlechte JA. Clinical practice. Prolactinoma. N Engl J Med. 2003;349: 2035-2041.
18. Le Moli R, EnDert E, Fliers E, MulDer T, Prummel MF, Romijn JA, Wiersinga WM. Establishment of reference values for endocrine tests. II. Hyperprolactinemia. Neth J Med. 1999;55:71-75.
19. FrieDewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-Density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
20. Bruins P, te Velthuis H, YazDanbakhsh AP, Jansen PG, Van HarDevelt FW, De Beaumont EM, WilDevuur CR, Eijsman L, Trouwborst A, Hack CE. Activation of the complement system during and after cardiopulmonary bypass surgery: postsurgery activation involves C-reactive protein and is associated with postoperative arrhythmia. Circulation. 1997;96: 3542-3548.
21. Galsgaard ED, Rasmussen BB, Folkesson CG, Christensen L, Berchtold MW, Rasmussen LM, Panina S. Re-evaluation of the prolactin receptor expression in human breast cancer. J Endocrinol. 2009;201:115-128.
22. Aziz MM, Ishihara S, Rumi MA, Mishima Y, Oshima N, Kadota C, Moriyama I, Li YY, Rahman FB, Otani A, Oka A, Ishimura N, Kadowaki Y, Amano Y, Kinoshita Y. Prolactin induces MFG-E8 production in macrophages via transcription factor C/EBP+-DepenDent pathway. Apoptosis. 2008;13:609-620.
23. Bresson JL, Jeay S, Gagnerault MC, Kayser C, Beressi N, Wu Z, Kinet S, DarDenne M, Postel-Vinay MC. Growth hormone (GH) and prolactin receptors in human peripheral blood mononuclear cells: relation with age and GH-binding protein. Endocrinology. 1999;140:3203-3209.
24. Sun R, Li AL, Wei HM, Tian ZG. Expression of prolactin receptor and response to prolactin stimulation of human NK cell lines. Cell Res. 2004;14:67-73.
25. Stattin P, Rinaldi S, Stenman UH, Riboli E, Hallmans G, Bergh A, Kaaks R. Plasma prolactin and prostate cancer risk: a prospective study. Int J Cancer. 2001;92:463-465.
26. Li H, Ahonen TJ, Alanen K, Xie J, LeBaron MJ, Pretlow TG, Ealley EL, Zhang Y, Nurmi M, Singh B, Martikainen PM, Nevalainen MT. Activation of signal transducer and activator of transcription 5 in human prostate cancer is associated with high histological graDe. Cancer Res. 2004;64:4774-4782.
27. Dagvadorj A, Collins S, Jomain JB, Abdulghani J, Karras J, Zellweger T, Li H, Nurmi M, Alanen K, Mirtti T, Visakorpi T, Bubendorf L, Goffin V, Nevalainen MT. Autocrine prolactin promotes prostate cancer cell growth via Janus kinase-2-signal transducer and activator of transcription-5a/b signaling pathway. Endocrinology. 2007;148:3089-3101.
28. Rudisch B, Nemeroff CB. EpiDemiology of comorbid coronary artery disease and Depression. Biol Psychiatry. 2003;54:227-240.
29. Boekholdt SM, Peters RJ, Day NE, Luben R, Bingham SA, Wareham NJ, Hack CE, Reitsma PH, Khaw KT. Macrophage migration inhibitory factor and the risk of myocardial infarction or Death due to coronary artery disease in adults without prior myocardial infarction or stroke: the EPIC-Norfolk Prospective Population study. Am J Med. 2004;117:390-397.